The Upside and Downside of PEGylation and the Emerging Alternatives

Wednesday, July 10, 2024

9:00 AM – 11:00 AM CET

Location: Sala Italia

Sponsored By

Development, physicochemical and biological characterization and validation of nanomedicines and biomedical nanotechnology-based approaches tailored to deliver therapeutic agents with distinct properties, such as small molecules, peptides, proteins, antibodies across biological barriers specifically targeting disease-associated molecules, cells, tissues or organs.

Learning Objectives:

At the completion of this activity, participants will know

The Lesser Evil: Do We Need Alternatives to PEG?
Strategies to Predict PEG-Associated Toxicities
Standardization of Anti-PEG Assays
Relevance of the Toxicities Observed in Animal Models

Chair(s)

KL

Katharina Landfester

Co-Chair(s)

Moein Moghimi, PhD (he/him/his)

Professor of Pharmaceutics and Nanomedicine
Newcastle University
Newcastle-upon-Tyne, United Kingdom

Speaker(s)

YB

Yechezkel (Chezy) Barenholz
Steve Roffler, PhD

Distinguished Research Fellow
Institute of Biomedical Science, Academia Sinica, Taipei, Taiwan (Republic of China)

PDF
KL

Katharina Landfester
Dmitri Simberg
Alexander Kabanaov, PhD, Dr. Sci.

Director, Center for Nanotechnology in Drug DeliveryMescal Swain Ferguson Distinguished Professor, UNC Eshelman School of PharmacyAdjunct Professor, UNC Department of Biomedical Engineering
University of North Carolina (UNC) at Chapel Hill
Chapel Hill, North Carolina, United States
Peter van Hoogevest, PhD (he/him/his)

CEO
Pharmanovation Consulting
Rheinfelden, Baden-Wurttemberg, Germany

PDF
Kumar Rajappan, PhD

Senior Director
Arcturus Therapeutics
San Diego, California, United States

PDF